Lidocaine 5% plasters (Versatis®)

Assessment Status Assessment process complete
Drug Lidocaine 5% plasters
Brand Versatis®
Indication For the symptomatic relief of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia, PHN).
Assessment Process
Rapid review commissioned 09/09/2010
Rapid review completed 22/10/2010
Rapid review outcome Full Pharmacoeconomic Assessment Recommended.
Full pharmacoeconomic assessment commissioned by HSE 10/06/2015
NCPE assessment completed 24/09/2015
NCPE assessment outcome Reimbursement Not Recommended

The NCPE concludes that the cost effectiveness of the 5% lidocaine plaster has not been demonstrated.

Technical Summary